Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO) announced a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL-based compound designed to selectively silence the BRD4 protein, a regulator of gene expression linked to proliferative and infectious diseases. The patent provides protection for PH-894’s chemical structure, genetic sequencing and broad therapeutic applications in the U.S.
According to Phio Pharmaceuticals, this allowance is a key milestone that strengthens its INTASYL intellectual property portfolio, which now includes 54 issued patents globally covering INTASYL chemistry, gene targets, immuno-oncology compounds and therapeutic uses. The company states this supports advancing PH-894 in the U.S. and pursuing strategic international collaborations.
Phio Pharmaceuticals (NASDAQ: PHIO) reported second quarter 2026 results and a business update focused on lead siRNA candidate PH-762. The company completed a 22-patient U.S. Phase 1b trial in skin cancers, is finalizing comprehensive study documentation for FDA submission, and plans to request an FDA meeting in Q3 2026 on next‑step trial design.
Phio initiated commercial-scale PH-762 API manufacturing and a long-term non-clinical toxicology study, both expected to finish by year-end, and reported new intellectual property actions, including three notices of allowance and one patent grant in the United States, Canada and Japan. Cash and cash equivalents were $13.0 million at June 30, 2026 versus $21.0 million at year-end 2025, with funding runway expected into the second half of 2027. Q2 2026 research and development expenses rose to $3.1 million (up 187% year-over-year), general and administrative expenses were $1.2 million, and net loss widened to $4.1 million from $2.2 million a year earlier. In April 2026, Phio established a $6.36 million at-the-market equity offering program and appointed dermatologist and former FDA advisory committee member Dr. R. Todd Plott to its Board of Directors.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series on Tuesday, July 28, 2026, at 12 PM EDT. CEO and Chairman Robert Bitterman will present an overview of the company’s proprietary INTASYL® siRNA gene silencing platform, highlighting lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session with investors. This announcement corrects the previously misstated day of the week. A replay may be available on Renmark’s website. Phio describes PH-762, which silences the PD-1 gene, as a potential non-surgical treatment for various skin cancers.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the appointment of R. Todd Plott, M.D., a board-certified dermatologist, researcher, inventor and former FDA advisory committee member, to its Board of Directors. Dr. Plott brings more than 30 years of experience in dermatologic care, clinical research and drug development.
According to Phio, he has overseen hundreds of clinical trials and contributed to advancing treatments for acne and other skin conditions. He is currently in private practice focusing on complex skin diseases, acne and skin cancer. Phio highlighted his expertise as the company advances PH-762 for squamous cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, reported new intellectual property milestones for its INTASYL® gene silencing technology. The company received three patent notices of allowance and one grant decision in the United States, Canada, and Japan, expanding protection of its INTASYL compounds and related innovations.
According to Phio Pharmaceuticals, these actions enhance its global patent portfolio, which now includes 54 issued patents covering INTASYL chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications in key countries, supporting its strategy for partnerships, R&D, and future commercialization.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on Tuesday, June 30, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the INTASYL siRNA platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
According to Phio, PH-762 is an INTASYL compound that silences the PD-1 gene implicated in various skin cancers and has been evaluated in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) will join a live virtual fireside chat hosted by Force Family Office on Monday, June 29, 2026 at 12 PM EDT. CEO Robert Bitterman and Dr. James Cardia will discuss siRNA therapy, skin cancer treatments, and Phio’s INTASYL® immuno-oncology program.
Phio Pharmaceuticals (NASDAQ: PHIO) reported a key milestone for its lead candidate PH-762. Nitto Denko Avecia has begun the first commercial-scale cGMP production of PH-762 drug substance under a services agreement signed in June 2025.
The new supply is intended to support an upcoming clinical trial in the next development phase of Phio's intratumoral program. Phio also recently completed a Phase 1b dose-escalation study of PH-762 for cutaneous carcinomas.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharma company, will participate in the Life Sciences Investor Forum on June 24-25, 2026.
CEO Robert Bitterman will present the INTASYL gene-silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by live Q&A and one-on-one meetings.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ Live Virtual Non-Deal Roadshow Series on Thursday, May 28, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the company’s INTASYL siRNA gene silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
PH-762, which silences the PD-1 gene, is in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.